Walleye Trading’s Tvardi Therapeutics TVRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-14
Closed -$5.37K 5522
2022
Q4
$5.37K Buy
+14
New +$5.32K ﹤0.01% 4578
2022
Q2
Sell
-297
Closed -$130K 5785
2022
Q1
$130K Buy
297
+105
+55% +$43.1K ﹤0.01% 4104
2021
Q4
$84K Buy
192
+45
+31% +$22.6K ﹤0.01% 4473
2021
Q3
$82K Buy
+147
New +$73.7K ﹤0.01% 4468
2020
Q2
Sell
-333
Closed -$159K 4680
2020
Q1
$159K Buy
+333
New +$181K ﹤0.01% 2804
2019
Q2
Sell
-1,400
Closed -$989K 4590
2019
Q1
$989K Buy
1,400
+1,122
+404% +$672K 0.01% 1672
2018
Q4
$130K Sell
278
-647
-70% -$417K ﹤0.01% 3734
2018
Q3
$798K Sell
925
-53
-5% -$38.3K ﹤0.01% 2352
2018
Q2
$674K Buy
+978
New +$497K ﹤0.01% 2538

Other funds holding TVRD

Walleye Trading's TVRD Position: Q2 2022 in Review

Walleye Trading sold out of Tvardi Therapeutics (TVRD) in Q2 2022, closing a stake of 284 shares — an estimated $124K sold.

Walleye Trading first reported a position in TVRD in Q3 2015 and held it in 4 quarters. The position peaked at $164K in Q4 2018. 178 funds tracked by Wall St. Rank hold TVRD as of Q2 2022.

  • Walleye Trading reported no remaining Tvardi Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Walleye Trading sold 284 Tvardi Therapeutics shares in Q2 2022, an estimated $124K.
  • Walleye Trading first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 4 quarters.
  • Walleye Trading's Tvardi Therapeutics position peaked at $164K in Q4 2018.
  • 178 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2022.

Based on Walleye Trading's 13F filing for Q2 2022, filed 8 Aug 2022.